AstraZeneca (AZN) said Thursday it has appointed Rick Suarez as US president and head of its US biopharmaceuticals business unit, effective immediately.
The company said Suarez will oversee the British pharmaceutical giant's $50 billion US research, development and manufacturing investment, which includes building a $4.5 billion manufacturing facility in Virginia.
Suarez previously served as AstraZeneca's country president for Spain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments